Intech Investment Management LLC Acquires New Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Intech Investment Management LLC bought a new position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 37,495 shares of the company’s stock, valued at approximately $52,000.

Other large investors also recently bought and sold shares of the company. GSA Capital Partners LLP raised its position in shares of Lyell Immunopharma by 1,285.5% in the third quarter. GSA Capital Partners LLP now owns 354,815 shares of the company’s stock valued at $490,000 after buying an additional 329,205 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Lyell Immunopharma by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 553,163 shares of the company’s stock worth $802,000 after acquiring an additional 69,712 shares during the period. American Century Companies Inc. raised its holdings in Lyell Immunopharma by 18.1% in the 2nd quarter. American Century Companies Inc. now owns 279,425 shares of the company’s stock valued at $405,000 after acquiring an additional 42,752 shares during the last quarter. Susquehanna Fundamental Investments LLC lifted its stake in shares of Lyell Immunopharma by 49.5% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 128,203 shares of the company’s stock worth $186,000 after purchasing an additional 42,452 shares during the period. Finally, TD Asset Management Inc boosted its holdings in shares of Lyell Immunopharma by 4.2% during the second quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock worth $1,457,000 after purchasing an additional 40,800 shares during the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Price Performance

Lyell Immunopharma stock opened at $0.90 on Monday. Lyell Immunopharma, Inc. has a 12-month low of $0.85 and a 12-month high of $3.26. The company has a market capitalization of $264.17 million, a price-to-earnings ratio of -1.14 and a beta of -0.45. The firm’s fifty day moving average price is $1.09 and its 200 day moving average price is $1.50.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Thursday, November 7th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.03. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The company had revenue of $0.03 million during the quarter. Analysts forecast that Lyell Immunopharma, Inc. will post -0.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LYEL has been the subject of several research analyst reports. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a research report on Tuesday, November 12th. Bank of America downgraded Lyell Immunopharma from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $6.00 to $1.00 in a report on Wednesday, October 30th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.